GATC Health’s Stem Cell Therapy for Diabetes

GATC Health Corp. announced a groundbreaking stem cell therapy for diabetes, detailed in a recent publication in the American Journal of Biomedical Science & Research. This autologous therapy uses a patient’s own stem cells to potentially treat both Type 1 and Type 2 diabetes, offering improved blood sugar control and reduced medication dependence. The process is […]
Adia Nutrition Enters Global Stem Cell Market – New Clinic in Winter Park, FL

Adia Nutrition, a publicly traded company, has opened a Florida clinic, Adia Med, offering stem cell treatments using ethically sourced umbilical cord stem cells. This clinic aims to provide convenient and FDA-compliant stem cell therapies, comparable to international clinics, for various conditions. The company highlights the quality of its stem cells, the convenience of a […]
CellFE Launches T-REST Kit: Revolutionizing CAR-T Cell Therapy Manufacturing for Breakthrough Cancer Treatments

CellFE, a pioneering biotechnology company, has unveiled its groundbreaking T-REST Resting T Cell Kit, a first-in-class solution designed to revolutionize CAR-T cell therapy manufacturing. This innovative kit aims to enhance the quality and efficacy of CAR-T therapies by optimizing the resting state of T cells, a critical factor in improving patient outcomes. By addressing key […]
NYSCF and Janssen Partner on Neurodegenerative Disease Drug Discovery

The New York Stem Cell Foundation Research Institute (NYSCF) and Janssen Research & Development, a Johnson & Johnson company, have partnered to accelerate the development of precision medicines for neurodegenerative diseases. NYSCF’s AI-powered platform, using automated stem cell systems, will be leveraged to identify new drug targets and therapies. This collaboration combines NYSCF’s expertise in stem cell […]
BioCentriq Expands Cell Therapy Manufacturing

This exciting news in the cell therapy sector could revolutionize how quickly life-changing therapies reach patients. BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), is set to expand its operations and establish a cutting-edge cell therapy manufacturing facility in Princeton, New Jersey. This facility will become BioCentriq’s new headquarters, marking a significant […]
Promising Phase 1 Results for Hemophilia A Gene Therapy

Expression Therapeutics announced promising Phase 1 clinical trial results for its novel gene therapy, ET3, treating hemophilia A. The trial, detailed in the New England Journal of Medicine, showed significant increases in Factor VIII levels and a reduction in bleeding events in participants with severe hemophilia A. The therapy uses a lentiviral vector targeting hematopoietic stem […]
FDA Grants Breakthrough Therapy Designation to Seres’ SER-155

Seres Therapeutics announced that the FDA granted Breakthrough Therapy designation to SER-155, their lead investigational drug, for reducing bloodstream infections in adults undergoing stem cell transplants. This designation is based on positive Phase 1b clinical trial data showing a significant reduction in infections compared to a placebo. A meeting with the FDA to discuss the […]
Eterna Therapeutics Investigates ERNA-101 in Cancer Models

Eterna Therapeutics, a preclinical-stage company, announced a research collaboration with MD Anderson Cancer Center to evaluate its lead induced mesenchymal stem cell therapy, ERNA-101, for treating ovarian and breast cancers. ERNA-101, a proprietary allogenic cell therapy, aims to stimulate antitumor immunity. The research will assess ERNA-101’s effects both in vitro and in vivo, with potential future studies exploring […]
FDA Approves StemCyte’s REGENECYTE™ Cord Blood Therapy

StemCyte Inc. announced FDA approval of its REGENECYTE™ cord blood stem cell therapy for treating blood and immune system disorders, making them the first U.S.-based biotech company to receive such a biologics license for this therapy in 2024. REGENECYTE™ is an allogeneic therapy derived from umbilical cord blood. The company is also exploring other applications […]
BioRestorative Therapies Expands Stem Cell Research with New York State License

In a significant advancement for regenerative medicine, BioRestorative Therapies, Inc. has secured a provisional license from the New York State Department of Health (NYSDOH) to process allogeneic (non-autologous) donor tissue material, including stem cells, for medical research. This expansion builds upon their previous authorization, which was limited to autologous (self-donated) mesenchymal stem cells. This new […]